SCHEMBL12376711

SCHEMBL12376711

CC(C)(C)NC(=O)CN(Cc1ccccc1)S(C)(=O)=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.61
ALDH1A1 P00352 5/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
POLB P06746 2/20 0.59
LMNA P02545 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
TSHR P16473 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.53
MAPT P10636 1/20 0.53
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14460020 0.81 GAA (0.70) GAAALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL13342376 0.80 LMNA (0.65) GAAALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL12406937 0.80 ALDH1A1 (0.71) GAAALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL13574865 0.79 GAA (0.67) GAAALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL13574870 0.79 ALDH1A1 (0.69) GAAALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL10312253 0.76 ALDH1A1 (0.64) GAAALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL13342148 0.75 HDAC1 (0.52) GAASMN1; SMN2POLBLMNACYP2C9
SCHEMBL24668557 0.74 CYP1A2 (1.00) GAAALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL24668314 0.73 LMNA (0.67) GAAALDH1A1SMN1; SMN2POLBLMNA
SCHEMBL20228914 0.73 ALDH1A1 (0.71) GAAALDH1A1SMN1; SMN2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003662-B2 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. (US) 2011-08-23 US disclosed
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ERBB2, LCK, SRC GAA 1103/4885ALDH1A1 1635/4885SMN1; SMN2 2264/4885
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 GAA 2295/4885ALDH1A1 1929/4885SMN1; SMN2 1840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.